A citation-based method for searching scientific literature

Leora Horn, Jeffrey R Infante, Karen L Reckamp, George R Blumenschein, Ticiana A Leal, Saiama N Waqar, Barbara J Gitlitz, Rachel E Sanborn, Jennifer G Whisenant, Liping Du, Joel W Neal, Jon P Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J Gibbons, Allison Holzhausen, Christine M Lovly, Heather A Wakelee. Clin Cancer Res 2018
Times Cited: 93



Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James, Jill S Clancy, Joseph Chen, Jean-François Martini, Antonello Abbattista, Benjamin J Solomon. Lancet Oncol 2017
Times Cited: 390




List of shared articles



Times cited

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
14

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
Pascale Tomasini, Julie Egea, Maxime Souquet-Bressand, Laurent Greillier, Fabrice Barlesi. Ther Adv Respir Dis 2019
20

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li,[...]. J Clin Oncol 2019
178

Treatment of brain metastases in ALK-positive non-small cell lung cancer.
Serena Ceddia, Giovanni Codacci-Pisanelli. Crit Rev Oncol Hematol 2021
3

First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development.
Danilo Rocco, Luigi Della Gravara, Ciro Battiloro, Cesare Gridelli. Expert Rev Respir Med 2022
1

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Yuankai Shi, Jian Fang, Xuezhi Hao, Shucai Zhang, Yunpeng Liu, Lin Wang, Jianhua Chen, Yi Hu, Xiaosheng Hang, Juan Li,[...]. Signal Transduct Target Ther 2022
1

Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Alice Indini, Erika Rijavec, Michele Ghidini, Claudia Bareggi, Donatella Gambini, Barbara Galassi, Paola Antonelli, Giulia Bettio, Clarissa Di Nubila, Francesco Grossi. Expert Opin Pharmacother 2020
6

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
M Majem, O Juan, A Insa, N Reguart, J M Trigo, E Carcereny, R García-Campelo, Y García, M Guirado, M Provencio. Clin Transl Oncol 2019
63

Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management.
Fabrizio Tabbò, Marco DE Filippis, Francesca Jacobs, Silvia Novello. Minerva Med 2022
1

Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists.
Kim Tam Bui, Wendy A Cooper, Steven Kao, Michael Boyer. J Clin Med 2018
22

New generation anaplastic lymphoma kinase inhibitors.
Angelo Delmonte, Marco Angelo Burgio, Alberto Verlicchi, Giuseppe Bronte, Paola Cravero, Paola Ulivi, Giovanni Martinelli, Lucio Crinò. Transl Lung Cancer Res 2019
12

Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer.
Hui Yu, Si Sun, Xingjiang Hu, Jinjing Xia, Jialei Wang, Haiquan Chen. Onco Targets Ther 2019
3

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
Elisabeth Smolle, Valentin Taucher, Joerg Lindenmann, Philipp J Jost, Martin Pichler. Cancers (Basel) 2021
7

Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I.
Archana Upadhya, Khushwant S Yadav, Ambikanandan Misra. Expert Opin Drug Deliv 2021
4

Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors.
J Tanner McMahon, Razan R Faraj, David Cory Adamson. Expert Opin Investig Drugs 2020
3

[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].
Peng Song, Li Zhang, Congcong Shang. Zhongguo Fei Ai Za Zhi 2018
3

Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Danilo Rocco, Ciro Battiloro, Luigi Della Gravara, Cesare Gridelli. Drug Saf 2019
8

Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
Fabrizio Tabbò, Francesco Passiglia, Silvia Novello. Curr Oncol Rep 2021
7

Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.
Xing Chang, Zi Liu, Shuai Man, Annie Roys, Zengqiang Li, Daiying Zuo, Yingliang Wu. RSC Adv 2019
0

The allure of 'ALUR'.
M Nagasaka, V W Zhu, S-H I Ou. Ann Oncol 2018
0

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
3

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
Anthony V Serritella, Christine M Bestvina. Thorac Surg Clin 2020
6

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Valerio Gristina, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, Viviana Bazan. Pharmaceuticals (Basel) 2020
29

Anaplastic lymphoma kinase inhibitors: an updated patent review (2014-2018).
Yi-Min Liu, Chun-Nan Kuo, Jing-Ping Liou. Expert Opin Ther Pat 2020
4

[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].
Yang Wang, Xiaobin Yuan, Jiayan Xiong, Zhidong Hao, Xingzhe Peng, Wanlin Chen, Lingling Cui, Hua Li, Xiulan Wang, Xiangbo He,[...]. Zhongguo Fei Ai Za Zhi 2020
2


Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
Niki Karachaliou, Manuel Fernandez Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell. Onco Targets Ther 2019
5

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
Bing Xia, Misako Nagasaka, Viola W Zhu, Sai-Hong Ignatius Ou, Ross A Soo. Transl Lung Cancer Res 2020
6

Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong. J Hematol Oncol 2019
69


Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance.
Zachary Schrank, Gagan Chhabra, Leo Lin, Tsatsral Iderzorig, Chike Osude, Nabiha Khan, Adijan Kuckovic, Sanjana Singh, Rachel J Miller, Neelu Puri. Cancers (Basel) 2018
72

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
453

Therapeutic Sequencing in ALK+ NSCLC.
Mei Elsayed, Petros Christopoulos. Pharmaceuticals (Basel) 2021
18

Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors.
Yuta Doi, Hiroaki Tagaya, Ayaka Noge, Kentaro Semba. Target Oncol 2022
0

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Leora Horn, Jennifer G Whisenant, Heather Wakelee, Karen L Reckamp, Huan Qiao, Ticiana A Leal, Liping Du, Jennifer Hernandez, Vincent Huang, George R Blumenschein,[...]. J Thorac Oncol 2019
83

The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.
Alessia Spagnuolo, Matteo Muto, Fabio Monaco, Giuseppe Colantuoni, Cesare Gridelli. Transl Lung Cancer Res 2019
2


[Therapeutic strategies in advanced ALK positive non-small cell lung cancer].
A Tiotiu, Y Billon, P Vaillant, O Menard, P Hofman, C Mascaux. Rev Mal Respir 2019
2

MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer.
Shijun Zhao, Donghui Hou, Xiaomin Zheng, Wei Song, Xiaoqing Liu, Sicong Wang, Lina Zhou, Xiuli Tao, Lv Lv, Qi Sun,[...]. Transl Lung Cancer Res 2021
8


Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura. Curr Cancer Drug Targets 2019
29

Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, Tingjun Hou. J Med Chem 2019
49

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.
Joseph A Pinto, Luis E Raez, Gelenis Domingo. Expert Rev Respir Med 2020
4